BioCardia, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
BioCardia, Inc. (BCDA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $63.51 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-03-24
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.32, a 0.00% change year-over-year.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2021-03-31 was $5.32.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $63.51, a 73.69% decline from fiscal 2023.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $241.35, a 2427.23% increase from fiscal 2022.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $9.55, a 79.51% increase from fiscal 2021.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2021 was $5.32.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $63.51 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | $63.09 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | $57.37 10-Q · filed 2024-08-13 | ||||
| 2023-12-31 | $241.35 10-K · filed 2025-03-26 | $16.09 10-K · filed 2024-03-27 | |||
| 2023-09-30 | $16.09 10-Q · filed 2023-11-08 | ||||
| 2022-12-31 | $9.55 10-K · filed 2023-03-29 | ||||
| 2022-09-30 | $9.55 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | $9.55 10-Q · filed 2022-08-10 | ||||
| 2022-03-31 | $5.32 10-Q · filed 2022-05-11 | ||||
| 2021-12-31 | $5.32 10-K · filed 2022-03-29 | ||||
| 2021-09-30 | $5.32 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $5.32 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $5.32 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |